Cite

HARVARD Citation

    Liefferinckx, C. et al. (2019). Impact of first‐line infliximab on the pharmacokinetics of second‐line vedolizumab in inflammatory bowel diseases. United European Gastroenterology journal. 7 (6), pp. 750-758. [Online]. 
  
Back to record